Journal of Critical Care
Volume 25, Issue 2 , Pages 214-220 , June 2010

Overuse of stress ulcer prophylaxis in the critical care setting and beyond

  • Christopher P. Farrell, DO

      Affiliations

    • Department of Internal Medicine Residency Program, Annenberg Conference Center, Lankenau Hospital, Wynnewood, PA 19096, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 215 850 2575; fax: +1 610 645 8141.
    • ,
  • Giancarlo Mercogliano, MD

      Affiliations

    • Division of Gastrointestinal Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA
    • ,
  • Catherine L. Kuntz, MD, MS

      Affiliations

    • Department of Internal Medicine Residency Program, Annenberg Conference Center, Lankenau Hospital, Wynnewood, PA 19096, USA
    • Division of Pulmonary and Critical Care Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA

References 

  1. Sessler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care. 2007;18(2):119–128
  2. Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care. 2005;20(1):35–45
  3. Martindale RG. Contemporary strategies for the prevention of stress-related mucosal bleeding. Am J Health Syst Pharm. 2005;62(10):S11–S17
  4. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994;330:377–381
  5. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200–2205
  6. Grube RRA, Byron MD. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64(13):1396–1400
  7. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944
  8. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. N Engl J Med. 1987;317(22):1376–1382
  9. Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–1106
  10. Elliot VS. Drug combination linked to clostridium outbreaks. Am Med News. 2004;47(24):42
  11. Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430–448
  12. Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med. 2007;2(2):86–92
  13. Patel GP, Liberman J, Gurka D, et al. Complications of critical illness: rational for prophylactic strategies. Clin Pulm Med. 2005;12(4):258–268
  14. Daley RJ, Rebuck JA, Welage LS, et al. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32(10):2008–2013
  15. Moldanado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923–936
  16. Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit. J Hosp Med. 2006;1(1):13–20
  17. Slattery E, Theyventhiran R, Cullen G, et al. Intravenous proton pump inhibitor use in hospital practice. Eur J Gastroenterol Hepatol. 2007;19(6):461–464
  18. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327
  19. Guillamondegui OD, Gunter OL, Bonaides JA, et al. Practice management guidelines for stress ulcer prophylaxis.. Eastern Association for the Surgery of Trauma; 2008;
  20. American Society of Health-System Pharmacists . ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Sys Pharm. 1999;56:347–379
  21. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004;61(6):588–596
  22. Mutlu GM, Mutlu EA, Factor P. Prevention and treatment of gastrointestinal complications in patients on mechanical ventilation. Am J Respir Med. 2003;2(5):395–411
  23. Gastrointestinal complications in patients on mechanical ventilation can be prevented and treated with various drugs. Drugs Ther Perspect. 2004;20(9):6–10
  24. Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1(3):192–216
  25. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events in patients treated with proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England. Br J Clin Pharmacol. 2000;50(4):366–372
  26. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–1122
  27. Ben-Menachem T, McCarthy BD, Fogel R, et al. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Crit Care Med. 1996;24(2):338–345
  28. Lu WY, Rhoney DH, Boling WB, et al. A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Neurosurgery. 1997;41(2):416–426

PII: S0883-9441(09)00128-2

doi: 10.1016/j.jcrc.2009.05.014

Journal of Critical Care
Volume 25, Issue 2 , Pages 214-220 , June 2010

Article Tools